White-Koning M - Search Results

1

Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.

Gallais F, Ysebaert L, Despas F, De Barros S, Dupré L, Quillet-Mary A, Protin C, Thomas F, Obéric L, Allal B, Chatelut E, White-Koning M. Gallais F, et al. Clin Pharmacokinet. 2020 Sep;59(9):1171-1183. doi: 10.1007/s40262-020-00884-0. Clin Pharmacokinet. 2020. PMID: 32328976 Free article.

2

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP. Thomas F, et al. Eur J Cancer. 2009 Sep;45(13):2316-23. doi: 10.1016/j.ejca.2009.05.007. Epub 2009 Jun 10. Eur J Cancer. 2009. PMID: 19523815

3

Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.

White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, Delord JP, Chatelut E, Vassal G. White-Koning M, et al. Clin Cancer Res. 2011 Jul 15;17(14):4862-71. doi: 10.1158/1078-0432.CCR-10-3278. Epub 2011 Jun 8. Clin Cancer Res. 2011. PMID: 21653689 Clinical Trial.

4

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Chatelut E, et al. Br J Cancer. 2012 Sep 25;107(7):1100-6. doi: 10.1038/bjc.2012.357. Epub 2012 Aug 28. Br J Cancer. 2012. PMID: 22929884 Free PMC article.

5

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J. Puisset F, et al. Br J Clin Pharmacol. 2013 Nov;76(5):734-40. doi: 10.1111/bcp.12098. Br J Clin Pharmacol. 2013. PMID: 23432476 Free PMC article. Clinical Trial.

6

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.

Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M. Chalret du Rieu Q, et al. Invest New Drugs. 2014 Oct;32(5):985-94. doi: 10.1007/s10637-014-0118-1. Epub 2014 May 31. Invest New Drugs. 2014. PMID: 24875134 Clinical Trial.

7

Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.

Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, Chatelut E, Ferron G. Chalret du Rieu Q, et al. Cancer Chemother Pharmacol. 2014 Sep;74(3):571-82. doi: 10.1007/s00280-014-2525-6. Epub 2014 Jul 23. Cancer Chemother Pharmacol. 2014. PMID: 25053386 Clinical Trial.

8

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, Thomas F. Imbs DC, et al. Invest New Drugs. 2016 Feb;34(1):41-8. doi: 10.1007/s10637-015-0304-9. Epub 2015 Nov 16. Invest New Drugs. 2016. PMID: 26572909 Clinical Trial.

9

Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, Chatelut E, Thomas F. Sauzay C, et al. Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10. Pharmacol Res. 2016. PMID: 27178732

10

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1. Pharmacol Res. 2016. PMID: 27378568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters